Salvage Therapy With Low-Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem Cell Transplantation

Salvage Therapy With Low-Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem Cell Transplantation

Bronchiolitis obliterans syndrome (BOS) is a life-threatening pulmonary manifestation of chronic graft versus host disease (cGVHD) post-allogeneic hematopoietic stem cell transplantation (HSCT), without clear standard of care. This study included 30 patients undergoing an allogeneic HSCT for a hemat...

Full description

Bibliographic Details
Main Authors: Yanmin Zhao, Guifang OuYang, Jimin Shi, Yi Luo, Yamin Tan, Jian Yu, Huarui Fu, Xiaoyu Lai, Lizhen Liu, He Huang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Pharmacology
Subjects:
ruxolitinib
bronchiolitis obliterans syndrome
allogeneic hematopoietic stem cell transplantation
chronic graft versus host disease
pulmonary function
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.668825/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.668825/full

Similar Items